# Captech Santé

> Captech Santé is a VC fund in Les Hauts-saint-jean backing Health Care and Biotechnology. See 10 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Les Hauts-saint-jean, France
- Total investments: 10
- Last investment: Feb 2026
- Lead investor: 30%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/captech-sant-nutrition

Captech Santé is a VC fund in Les Hauts-saint-jean focused on Health Care and Biotechnology. CAPTECH Santé Nutrition fund invests in biotechnology, health, and nutrition projects, managed by experts in life sciences and supported by FINORPA Gestion.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 40% |
| Biotechnology | 4 | 40% |
| Medical | 2 | 20% |
| Pharmaceutical | 2 | 20% |
| Delivery | 1 | 10% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 40% |
| Venture - Series Unknown | 3 | 30% |
| Seed | 2 | 20% |
| Series B | 1 | 10% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Bon Vivant | A French biotechnology startup founded by Hélène Briand, and Stéphane Mac Millan that leverages precision fermentation technology to develop plant-based milk using yeast to create non-dairy alternatives that are similar in texture and taste to its counterparts. | $29.4M | Series A | Feb 24, 2026 |  |
| Lattice Medical | Today 1 women on 8 has a breast cancer, 40% of them will have a mastectomy to cure cancer and only 14% of them will have reconstruction because actual technics does no fit for breast reconstruction. That’s why LATTICE MEDICAL develops the implantable device MATTISSE which answer to clinical and societal issues and allow women to get back theirbodies and life. MATTISSE implant allows a natural reconstruction by regenerating autologous adipose tissues, custom reconstruction thanks to 3D printing and single surgery due to fully biodegradable material, which fully disappear after reconstruction. We aim in long term to replace silicon-based implant by our technology. | $50M | Series B | Oct 24, 2025 |  |
| Genoskin | Genoskin is a biotech company that leverages its expertise in skin biology and immunology to enhance the development of medications and vaccines. | $5.4M | Series A | Sep 16, 2025 |  |
| Hemerion | Hemerion is focused on creating innovative cancer treatments. The focus is on cutting-edge methods to treat glioblastoma, the most prevalent and dangerous primary brain tumour. | $2.8M | Series A | May 22, 2025 |  |
| Vetbiolix | Développement clinique de solutions thérapeutiques innovantes pour le marché vétérinaire chiens & chats : oncologie & pathologies chroniques | $4.2M | Venture - Series Unknown | Dec 06, 2024 |  |
| Vaxinano | Vaxinano is a biotechnology company specialized in preclinical and pharmaceutical development of human and veterinary vaccines and drug delivery systems. Vaxinano was created in 2016, building on 25 years of research and clinical trials on vaccines and the patented technology of Pr Didier Betbeder. | $6.5M | Venture - Series Unknown | Oct 29, 2024 |  |
| Vetbiolix | Développement clinique de solutions thérapeutiques innovantes pour le marché vétérinaire chiens & chats : oncologie & pathologies chroniques | $2.8M | Seed | Sep 08, 2024 |  |
| Nutriearth | Nutriearth is a biotech firm that develops nutritional ingredients for human and animal health. | $8.6M | Venture - Series Unknown | Jul 01, 2024 |  |
| Bon Vivant | A French biotechnology startup founded by Hélène Briand, and Stéphane Mac Millan that leverages precision fermentation technology to develop plant-based milk using yeast to create non-dairy alternatives that are similar in texture and taste to its counterparts. | $15.9M | Seed | Oct 11, 2023 |  |
| Lattice Medical | Today 1 women on 8 has a breast cancer, 40% of them will have a mastectomy to cure cancer and only 14% of them will have reconstruction because actual technics does no fit for breast reconstruction. That’s why LATTICE MEDICAL develops the implantable device MATTISSE which answer to clinical and societal issues and allow women to get back theirbodies and life. MATTISSE implant allows a natural reconstruction by regenerating autologous adipose tissues, custom reconstruction thanks to 3D printing and single surgery due to fully biodegradable material, which fully disappear after reconstruction. We aim in long term to replace silicon-based implant by our technology. | $7.8M | Series A | Oct 01, 2022 |  |

10 of 10 investments shown.

## Co-investors
- [Nord France Amorcage](https://shizune.co/investors/profile/nord-france-amorcage) — VC Fund, 7 deals together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 6 deals together
- [Finovam Gestion](https://shizune.co/investors/profile/finovam-gestion) — VC Fund, 3 deals together
- [Blast. Club](https://shizune.co/investors/profile/blast-club) — VC Fund, 2 deals together
- [Founders Future](https://shizune.co/investors/profile/founders-future) — VC Fund, 2 deals together
- [OCCTE](https://shizune.co/investors/profile/occte) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Captech Santé invest in?

Captech Santé invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Venture - Series Unknown stage. Most of the 10 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Captech Santé last invest?

The most recent investment recorded for Captech Santé closed in Feb 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co